clascoterone topical (Rx)

Brand and Other Names:Winlevi
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

topical cream

  • 1%

Acne Vulgaris

Indicated for acne vulgaris in patients aged ≥12 years

Apply thin layer topically to affected area BID

Dosage Forms & Strengths

topical cream

  • 1%

Acne Vulgaris

Indicated for acne vulgaris in patients aged ≥12 years

<12 years: Safety and efficacy not established

≥12 years: Apply thin layer topically to affected area BID

Next:

Adverse Effects

>10%

Adverse effects listed below for the drug were similar to those for the vehicle cream in clinical trials

Erythema/redness (12.2%)

Scaling/dryness (10.5%)

1-10%

Adverse effects listed below for the drug were similar to those for the vehicle cream in clinical trials

Pruritus (7.7%)

Stinging/burning (4.2%)

Edema (3.6%)

Striae rubrae (2.5%)

Skin atrophy (1.6%)

Telangiectasia (1.2%)

Frequency Not Defined

Metabolism: Hyperkalemia

Reproductive: Polycystic ovaries, amenorrhea

Previous
Next:

Warnings

Contraindications

None

Cautions

May induce local irritation (eg, erythema, redness, pruritus, scaling, dryness); limit concomitant use with other potentially irritating topical products that have a strong drying effect or have high concentrations of alcohol, astringents, spices, or lime

HPA axis suppression

  • Hypothalamic-pituitary-adrenal (HPA) axis suppression observed in clinical trials; may occur during or after treatment
  • Conditions that increase systemic absorption include use over large surface areas, prolonged use, and occlusive dressings
  • If HPA axis suppression develops, attempt to withdraw the drug
  • Pediatric patients may be more susceptible to systemic toxicity
Previous
Next:

Pregnancy & Lactation

Pregnancy

No data are available on use in pregnant females to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Animal studies

  • Subcutaneous administration to pregnant rats and rabbits during organogenesis at doses 8 or 39 times the maximum recommended human dose, respectively, increased malformations in rats and postimplantation loss and resorptions in rabbits

Lactation

Data are not available regarding presence of clascoterone or metabolite in human milk, effects on breastfed infants, or effects on milk production

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Exact mechanism of action is unknown; laboratory studies suggest clascoterone competes with androgens, specifically dihydrotestosterone, for binding to the androgen receptors within the sebaceous gland and hair follicles

Absorption

Measured on Day 14 of BID dosing

Peak plasma concentration: 4.5 ng/mL

Average plasma concentration: 1.9 ng/mL

AUC: 37 ng⋅hr/mL

Steady-state achieved on Day 5

Distribution

Protein bound: 84-89%

Metabolism

Plasma concentrations of cortexolone, a possible primary metabolite, were detectable and generally below or near the lower limit of quantitation (0.5 ng/mL)

Elimination

Excretion: Not characterized

Previous
Next:

Administration

Topical Administration

For topical use only; not for ophthalmic, oral, or vaginal use

Gently cleanse affected area; after skin is dry, apply thin uniform layer of cream to affected area(s) twice per day (morning and evening)

Do not apply to cuts, abrasions, or eczematous or sunburned skin

Avoid concomitant use of other potentially irritating topical products

Avoid accidental transfer of cream into eyes, mouth, or other mucous membranes; if this occurs, rinse thoroughly with water

Storage

Before dispensing: Refrigerate at 36-46ºF (2-8ºC)

After dispensing to patient: Store at room temperature of 68-77ºF (20-25ºC); discard unused product 180 days after dispensing or 1 month after first opening, whichever is sooner

Do not freeze

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.